Inositol is a cyclic polyol (a sugar alcohol with a six-carbon ring structure) that is the foundation of the phosphatidylinositol (PI) signalling pathway — one of the most important intracellular signalling pathways in the human body, regulating cell growth, calcium signalling, insulin action, and the response to osmotic stress. Inositol is synthesised in the body from glucose-6-phosphate via the enzyme inositol-3-phosphate synthase (INPP1), and it is also obtained from dietary sources including fruits, nuts, grains, and particularly from the phytic acid that is present in whole grains and legumes. Inositol is the precursor of the phosphatidylinositol (PI) lipids that are embedded in the inner leaflet of the cell membrane and that are the substrate for the phospholipase C (PLC) signalling pathway, which generates the two second messengers inositol trisphosphate (IP3) and diacylglycerol (DAG) from the phosphatidylinositol bisphosphate (PIP2) that is present in the inner leaflet of the cell membrane. The inositol-dependent PI signalling pathway is one of the most evolutionarily ancient and most widely used signalling pathways in eukaryotes, and its dysfunction is implicated in some of the most common metabolic and psychiatric conditions of modern civilisation, including insulin resistance, polycystic ovary syndrome (PCOS), panic disorder, and depression.
The Phospholipase C Signalling Pathway
The phospholipase C (PLC) signalling pathway is the primary mechanism by which the inositol-derived phosphatidylinositol lipids generate intracellular signals. When a receptor on the cell surface is activated by its ligand (which may be a hormone, a growth factor, a neurotransmitter, or another signalling molecule), it activates a specific PLC isoform (PLC-beta, PLC-gamma, PLC-delta, or PLC-epsilon, depending on the receptor type) through a G-protein-coupled mechanism (for PLC-beta) or through a receptor tyrosine kinase-coupled mechanism (for PLC-gamma). The activated PLC then hydrolyses the PIP2 that is present in the inner leaflet of the cell membrane, generating IP3 (inositol trisphosphate) and DAG (diacylglycerol). IP3 diffuses to the endoplasmic reticulum, where it binds to the IP3 receptor (a calcium release channel on the ER membrane) and triggers the release of calcium from the ER into the cytoplasm. The calcium that is released by IP3 then activates the calcium-dependent signalling pathways that regulate cell growth, proliferation, secretion, and contraction. DAG remains in the membrane, where it activates protein kinase C (PKC), which then phosphorylates its target proteins and regulates a wide range of cellular responses.
The clinical importance of the inositol-dependent PI signalling pathway is underscored by the conditions that are associated with its dysfunction. In insulin resistance, the impairment of the PI3-kinase (PI3K) arm of the insulin signalling pathway (which generates phosphatidylinositol (3,4,5) trisphosphate, PI(3,4,5)P3, from PI(4,5)P2) leads to the impaired glucose uptake, the impaired glycogen synthesis, and the compensatory hyperinsulinemia that characterise the metabolic syndrome and type 2 diabetes. In PCOS, the hyperinsulinemia that results from insulin resistance stimulates the theca cells of the ovary to produce excess androgens, producing the anovulation, the hirsutism, and the polycystic ovarian morphology that characterise this condition. In panic disorder and depression, the dysregulation of the IP3 and DAG signalling pathways in neurons is associated with the calcium signalling abnormalities and the altered neuronal excitability that may underlie these conditions.
Inositol for PCOS
Inositol (particularly myo-inositol and D-chiro-inositol, the two stereoisomers that are most relevant to human metabolism) has been studied extensively as a treatment for polycystic ovary syndrome (PCOS). Multiple RCTs have demonstrated that inositol supplementation at 2-4g daily (of myo-inositol, alone or in combination with D-chiro-inositol) improves insulin sensitivity, reduces the circulating insulin and androgen levels, restores ovulatory function, and improves pregnancy rates in women with PCOS. A meta-analysis of 13 RCTs in women with PCOS found that inositol supplementation significantly improved the ovulation rate (by approximately 30%), the pregnancy rate (by approximately 40%), and the markers of insulin sensitivity (fasting insulin, HOMA-IR) compared to placebo. The evidence for inositol in PCOS is moderately strong, and inositol is considered a first-line treatment for the insulin resistance and the metabolic dysfunction that underlie PCOS in many expert clinical guidelines.
Inositol for Panic Disorder
Inositol has also been studied as a treatment for panic disorder, with compelling results. A double-blind RCT in 21 patients with panic disorder found that inositol supplementation at 12g daily (in divided doses) significantly reduced the frequency and severity of panic attacks and improved the scores on the Panic Disorder Severity Scale (PDSS) compared to placebo, with benefits that were apparent within the first 4 weeks of treatment. The proposed mechanism of the inositol benefit in panic disorder is the inositol-induced normalisation of the IP3 and DAG signalling pathways in neurons, which reduces the neuronal excitability and the calcium signalling abnormalities that may underlie the panic response. Inositol is generally well-tolerated with no significant adverse effects at the high doses that are used for panic disorder (12-18g daily), though very high doses can produce mild GI upset and diarrhoea.
Practical Application
For general inositol supplementation, the evidence-based dose is 2-4g of myo-inositol daily (for PCOS and for general metabolic support) or 12-18g of myo-inositol daily (for panic disorder, under medical supervision). For the treatment of PCOS, the combination of myo-inositol and D-chiro-inositol (in the 40:1 ratio that is found in the body) is the most evidence-based approach, because it addresses both the insulin signalling defect (myo-inositol) and the androgen excess (D-chiro-inositol) that are the two primary drivers of PCOS. Inositol is generally well-tolerated with no significant adverse effects at therapeutic doses, though very high doses can produce mild GI upset and a fishy body odour. For comprehensive metabolic and neurological support, inositol pairs well with the omega-3 fatty acids (which are the precursors of the DHA that is essential for neuronal membrane composition and which have independent benefits for insulin sensitivity), with alpha-lipoic acid (which improves insulin sensitivity and which supports the PI3K arm of the insulin signalling pathway), with the B-complex vitamins (which are required for the function of the inositol metabolism enzymes), and with the Mediterranean dietary pattern (which is associated with better insulin sensitivity and with reduced risk of the metabolic syndrome).
Leave a Reply